Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.

Tree AC, Hinder V, Chan A, Tolan S, Ostler P, van der Voet H, Kancherla K, Loblaw A, Naismith O, Jain S, Martin A, Price D, Brand D, Chu W, Duffton A, Kelly P, O'Neill B, Staffurth J, Sasso G, Pugh J, Manning G, Brown S, Burnett S, Griffin C, Hall E, van As N, PACE Investigators

Open source

DOI: 10.1016/s1470-2045(25)00205-0
Published: 2025 Jul
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00205-0,
  title = {Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.},
  author = {Tree AC and Hinder V and Chan A and Tolan S and Ostler P and van der Voet H and Kancherla K and Loblaw A and Naismith O and Jain S and Martin A and Price D and Brand D and Chu W and Duffton A and Kelly P and O'Neill B and Staffurth J and Sasso G and Pugh J and Manning G and Brown S and Burnett S and Griffin C and Hall E and van As N and PACE Investigators},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00205-0},
  url = {https://doi.org/10.1016/s1470-2045(25)00205-0}
}

RIS

TY  - JOUR
TI  - Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.
AU  - Tree AC
AU  - Hinder V
AU  - Chan A
AU  - Tolan S
AU  - Ostler P
AU  - van der Voet H
AU  - Kancherla K
AU  - Loblaw A
AU  - Naismith O
AU  - Jain S
AU  - Martin A
AU  - Price D
AU  - Brand D
AU  - Chu W
AU  - Duffton A
AU  - Kelly P
AU  - O'Neill B
AU  - Staffurth J
AU  - Sasso G
AU  - Pugh J
AU  - Manning G
AU  - Brown S
AU  - Burnett S
AU  - Griffin C
AU  - Hall E
AU  - van As N
AU  - PACE Investigators
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00205-0
UR  - https://doi.org/10.1016/s1470-2045(25)00205-0
ER  -

APA

AC, T., V, H., A, C., S, T., P, O., H, V. D. V., K, K., A, L., O, N., S, J., A, M., D, P., D, B., W, C., A, D., P, K., B, O., J, S., G, S., J, P., G, M., S, B., S, B., C, G., E, H., N, V. A., & Investigators, P. (2025). Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00205-0

Source records

pubmed · retrieved 2026-09-25T22:51:24.596Z